Due to the overexpression of FGFR4 in ovarian cancer and its role in promoting cancer cell proliferation, FGFR4 inhibitors have therapeutic potential in ovarian cancer [17,18]. The gene discussed is FGFR4; the disease is ovarian carcinoma.